Clinical impact or potential implications. Response to immunosuppression and antifibrotic therapy is variable in patients with connective tissue disease-related fibrosing interstitial lung disease. Data from prospective clinical trials and longitudinal registry studies will conceivably provide additional insight into improving care for these patients.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- rheumatoid arthritis
- clinical trial
- idiopathic pulmonary fibrosis
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- prognostic factors
- peritoneal dialysis
- quality improvement
- patient reported outcomes
- pain management
- mesenchymal stem cells
- phase ii
- open label
- cell therapy
- pulmonary fibrosis